Home / News / Events / Events detail
On the 24th of February, the "CADD to AIDD - Technologies to Break Excessive Competition in New Drug Development?" salon was conducted successfully in Shanghai and virtually. The speakers included Viva scientists, academic experts, founders of AI pharmaceutical companies, and R&D representatives who convened to discuss the current trends in CADD/AIDD development and innovative drug development strategies.
(To watch the full video playback, please visit BiliBili.)
Dr. Yue Qian, Senior Director of the Biology Department at Viva
Computer Aided Drug Design (CADD) - The Key to Accelerating the Drug Design Process
Dr. Yue Qian provided valuable insights into how computer-aided drug design (CADD) can accelerate the drug design process. Dr. Qian discussed the implementation of essential computational tools in CADD, such as site identification, hit generation, lead optimization, and others, through case studies.
Dr. Mingyue Zheng, Shanghai Institute of Materia Medica. Chinese Academy of Sciences
AI-Based Drug-Target Interaction Prediction
The prediction of drug-target interaction (DTI) has always been a challenging and fundamental issue in drug design. During the salon, Dr. Zheng put forth a novel idea that drug-target interaction recognition could be compared to the face recognition problem and presented several case studies on sequence-based drug-target interaction prediction, transcriptome-based drug-target interaction prediction, and AI-based multi-target drug design. Additionally, he emphasized that more research is needed to achieve greater accuracy for DTI.
Panel: New Approaches to Drug R&D -- How AI+ Empowers Drug Innovation
During the panel discussion, Dr. Han Dai, CIO of Viva Biotech and Head of Viva BioInnovator, served as the host. The esteemed panel consisted of five industry experts: Dr. Yun Tang, Professor of East China University of Science and Technology and Founder of KangRenHuiCheng; Dr. DaQiang Xu, Founder and CEO of AIxplorerBio; Dr. Mingxi Li, CEO of Apeiron; Dr. Feng Ren, Co-CEO, CSO and Head of Drug Development of Insilico Medicine; and Dr. Peiyu Zhang, Chief Scientific Officer of XtalPi (from left to right). The focus of the discussion was "New Approaches to Drug Development: How AI+ Empowers Drug Innovation" The panelists engaged in an insightful and productive exchange of ideas and perspectives.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us